The global Preterm Birth and PROM Testing Market was valued at USD 227.8 million in 2023 and is projected to expand at a CAGR ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

Last week, readers were most interested in a story about a lawsuit brought forth by Qiagen against BioMérieux in Germany.

QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...

Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent in ...

(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...

Today G&GR welcomes long time member and first time contributor, John Tynan, to the writing ranks. Take it away JT: Welcome to The Pub Test, where rugby opinions flow as freely as the beer and ...

Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company ...

The test is designed to screen for genetic markers associated with celiac disease, an autoimmune condition affecting the intestine. Credit: Jo Panuwat D / Shutterstock. The US Food and Drug ...